U.S. study suggests that semaglutide, a glucagon-like peptide 1 (GLP-1) receptor agonist, may be useful to reduce alcohol consumption and craving in alcohol use disorder.
The research paper shows the life expectancy for 20-year-old men living with HIV between 2012 and 2020 rose to 68 years old while for women it only increased to 61 years old.